์ธํํฌ๋ ์ฌ ํ๋ก์ธํธ
**์ธํํฌ๋ ์ฌ ํ๋ก์ธํธ(Cefpodoxime proxetil)**์ ์ฃผ๋ก ๊ฐ์์ ๊ฐ์์ฑ ์ธ๊ท ๊ฐ์ผ, ํนํ ํผ๋ถ ๊ฐ์ผ ์น๋ฃ์ ์ฌ์ฉ๋๋ ๊ฒฝ๊ตฌ์ฉ 3์ธ๋ ์ธํ๋ก์คํฌ๋ฆฐ๊ณ ํญ์์ ์ ๋๋ค. * **์ ๊ตฌ์ฝ๋ฌผ ์ ์ **: ์์คํ ๋ฅดํ๋ "ํ๋ก์ธํธ" ์ฑ๋ถ์ด ์ง์ฉ์ฑ๊ณผ ์์ฅ๊ด ํก์๋ฅผ ๋์ฌ์ค๋๋ค. ํก์๋ ํ ์ฅ๋ฒฝ์์ ํ์ฑ ๋์ฌ์ฐ๋ฌผ์ธ ์ธํํฌ๋ ์ฌ์ผ๋ก ๋น ๋ฅด๊ฒ ๊ฐ์๋ถํด๋ฉ๋๋ค. * **ํญ๊ท ์คํํธ๋ผ**: ๊ทธ๋ ์์ฑ๊ท (๊ฐ์ค๊ฐํฌ๋์๊ตฌ๊ท , ํฉ์ํฌ๋์๊ตฌ๊ท , ๊ฐ์ฐ์์๊ตฌ๊ท ๋ฑ) ๋ฐ ๋ง์ ๊ทธ๋ ์์ฑ ์ฅ๋ด์ธ๊ท ๊ณผ(๋์ฅ๊ท , ํ๋กํ ์ฐ์ค ๋ฏธ๋ผ๋น๋ฆฌ์ค, ํ์คํด๋ ๋ผ ๋ฌผํ ์๋ค, ํด๋ ๋ธ์์๋ผ ๋ฑ)์ ๋งค์ฐ ํจ๊ณผ์ ์ ๋๋ค. * **์์์ ํน์ง**: ๋ น๋๊ท , ์ฅ๊ตฌ๊ท , ํ๊ธฐ์ฑ๊ท ๋ฐ ๋ฉํฐ์ค๋ฆฐ ๋ด์ฑ ํฌ๋์๊ตฌ๊ท (MRSA/MRSP)์๋ ํจ๊ณผ๊ฐ ์์ต๋๋ค. ๊ฐ์์ 1์ผ 1ํ ํฌ์ฌ๊ฐ ๊ฐ๋ฅํ์ฌ ์ธํ๋ ์ ๊ณผ ๊ฐ์ 1์ธ๋ ์ธํ๋ก์คํฌ๋ฆฐ์ ๋นํด ๋ณดํธ์์ ํฌ์ฝ ์์๋๋ฅผ ํฌ๊ฒ ๋์ฌ์ค๋๋ค.
์์ฉ ๊ธฐ์ : Cefpodoxime is a **bactericidal** antibiotic that disrupts bacterial cell wall synthesis. * It binds to specific **Penicillin-Binding Proteins (PBPs)** located inside the bacterial cell wall. * Inhibition of PBPs โ prevents the cross-linking of peptidoglycan chains โ weakens the bacterial cell wall. * This structural instability โ osmotic pressure changes โ **cell lysis** and death. * As a third-generation cephalosporin, it exhibits increased stability against many bacterial **beta-lactamase** enzymes compared to earlier generations.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- For susceptible skin and soft tissue infections ยท 5 mg/kg PO q12h or 10 mg/kg PO once daily ยท PO ยท q12h or q24h ยท Extrapolated from human dosage.
- Foals (neonates) with bacterial infections ยท 10 mg/kg PO q6-12 hours ยท PO ยท q6-12h ยท Additional studies required to confirm clinical efficacy and safety.
- For susceptible skin infections ยท 5-10 mg/kg PO once daily ยท PO ยท q24h ยท 5-7 days or 2-3 days beyond cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen. ยท May be given with or without food.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypersensitivity to cefpodoxime or other cephalosporins
์ด์๋ฐ์
- Inappetence
- Diarrhea
- Vomiting
- Hypersensitivity reactions
- Positive direct Coombs' test
- Blood dyscrasias (rare, following high doses)
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides / Nephrotoxic drugs (e.g., amphotericin B) ยท Potentially additive nephrotoxicity (controversial). In vitro synergy exists, but do not mix together in the same syringe/fluid.
- Antacids ยท Drugs that increase stomach pH may decrease the absorption of cefpodoxime.
- H-2 Antagonists (ranitidine, famotidine) ยท Drugs that increase stomach pH may decrease the absorption of cefpodoxime.
- Probenecid ยท Competitively blocks tubular secretion of cephalosporins, increasing serum levels and half-lives.
- Proton Pump Inhibitors (omeprazole) ยท Drugs that increase stomach pH may decrease the absorption of cefpodoxime.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (resolution of infection)
- Adverse GI effects
๊ณผ์ฉ๋
Cephalosporin overdoses are unlikely to cause significant problems. The most likely signs of acute toxicity or overdose are gastrointestinal disturbances (vomiting, diarrhea, inappetence). Supportive care should be provided if necessary.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.